ADVENTRX PHARMACEUTICALS, INC.

Nov 10, 09
	NEW STORY
16:05 ET	ADVENTRX Pharmaceuticals Reports Third Quarter Financial Results
Oct 22, 09
09:00 ET	ADVENTRX Pharmaceuticals to Present at the BIO Investor Forum on October 29
Oct 20, 09
07:00 ET	ADVENTRX Provides Business Update Following Recent Financing Activity
Oct 15, 09
16:15 ET	ADVENTRX Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26
Oct 09, 09
13:17 ET	ADVENTRX Pharmaceuticals Announces Closing of Financing
Oct 06, 09
09:33 ET	ADVENTRX Pharmaceuticals Announces Financing
Sep 14, 09
16:05 ET	ADVENTRX Intends Voluntary Withdrawal From NYSE Amex Upon Approval of NASDAQ Listing
Aug 12, 09
16:05 ET	ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results
Aug 10, 09
16:05 ET	ADVENTRX Pharmaceuticals Announces Closing of Financing
Aug 05, 09
16:05 ET	ADVENTRX to Hold Second Quarter Results and Business Update Conference Call on August 12
12:48 ET	ADVENTRX Pharmaceuticals Announces Financing
Jul 06, 09
17:00 ET	ADVENTRX Pharmaceuticals Announces Closing of Financing
Jun 29, 09
16:31 ET	ADVENTRX Pharmaceuticals Announces Financing
09:00 ET	ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Jun 15, 09
08:00 ET	ADVENTRX Pharmaceuticals Announces Closing of Financing
Jun 08, 09
10:28 ET	ADVENTRX Pharmaceuticals Announces Financing
Jun 02, 09
16:12 ET	ADVENTRX Receives Notice From NYSE Amex
May 12, 09
18:20 ET	ADVENTRX Pharmaceuticals Reports First Quarter 2009 Financial Results
May 07, 09
16:35 ET	ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Mar 25, 09
09:02 ET	ADVENTRX Grants Exclusive Rights to ANX-514 in South Korea
09:01 ET	ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Mar 20, 09
16:01 ET	ADVENTRX Announces Further Cost-Cutting Measures
Feb 10, 09
09:00 ET	ADVENTRX Provides Update on Strategic Transaction Process
Feb 05, 09
06:00 ET	ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Jan 05, 09
16:01 ET	ADVENTRX Announces Further Cost-Cutting Measures
Dec 15, 08
09:00 ET	ADVENTRX Exploring Strategic Options
Nov 06, 08
16:01 ET	ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
Nov 04, 08
06:00 ET	ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
Oct 30, 08
06:00 ET	ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results
Oct 20, 08
06:00 ET	ADVENTRX Announces Restructuring and Cost Reduction Initiatives
Aug 11, 08
16:01 ET	ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
Aug 08, 08
06:00 ET	ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
Jul 01, 08
06:00 ET	ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
Jun 30, 08
06:00 ET	ADVENTRX Settles Dispute With Former Licensee
Jun 16, 08
06:00 ET	ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
Jun 03, 08
06:00 ET	ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
May 16, 08
06:00 ET	ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
May 13, 08
06:00 ET	ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
May 12, 08
06:00 ET	ADVENTRX Pharmaceuticals Reports First Quarter 2008 Financial Results
May 05, 08
06:00 ET	ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
Apr 15, 08
06:00 ET	ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
Apr 09, 08
06:00 ET	ADVENTRX Appoints Vice President of Manufacturing
Apr 03, 08
15:00 ET	ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer
Mar 31, 08
06:00 ET	ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
Mar 13, 08
16:01 ET	ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Mar 12, 08
06:00 ET	ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Mar 10, 08
06:00 ET	Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
Mar 06, 08
06:00 ET	ADVENTRX Pharmaceuticals to Report Fourth Quarter and Year End 2007 Results
Feb 25, 08
06:00 ET	Eric K. Rowinsky Joins ADVENTRX Board of Directors
Feb 07, 08
06:00 ET	ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
Feb 05, 08
06:00 ET	ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference
Jan 31, 08
06:00 ET	ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
Jan 30, 08
06:00 ET	ADVENTRX Announces Consolidation of Clinical and Management Positions
Jan 14, 08
06:30 ET	ADVENTRX Announces ANX-530 Safety Data and Provides NDA Submission Guidance
Dec 10, 07
06:00 ET	ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference
Dec 05, 07
06:00 ET	ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
Nov 16, 07
06:00 ET	ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
Nov 07, 07
16:01 ET	ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
Nov 05, 07
06:00 ET	ADVENTRX Pharmaceuticals to Present at the 13th Annual BIO-Europe Partnering Conference
Nov 02, 07
08:00 ET	ADVENTRX Provides Update on Cofactor(R) Program
Nov 01, 07
06:00 ET	ADVENTRX Pharmaceuticals to Present at the 9th Annual Acumen BioFin Rodman & Renshaw Healthcare Conference
Oct 31, 07
06:00 ET	ADVENTRX Pharmaceuticals to Present at the 18th Annual CIBC Healthcare Conference
Oct 30, 07
06:00 ET	ADVENTRX Pharmaceuticals to Present at the 2007 BIOCOM Investor Conference
Oct 25, 07
15:30 ET	ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
Oct 10, 07
06:00 ET	ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
Oct 08, 07
06:00 ET	ADVENTRX Appoints Vice President of Commercialization
Oct 05, 07
15:41 ET	ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
Oct 01, 07
06:00 ET	ADVENTRX Pharmaceuticals Announces Results From Phase 2b Clinical Trial of ANX-510 (CoFactor(R))
00:09 ET	ADVENTRX Pharmaceuticals to Report Results from Phase 2b Clinical Trial of ANX-510 (CoFactor(R))
00:09 ET	ADVENTRX Pharmaceuticals to Report Results from Phase 2b Clinical Trial of ANX-510 (Cofactor(R))
Sep 27, 07
06:00 ET	ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
Sep 20, 07
06:00 ET	ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
Sep 13, 07
06:00 ET	ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners' Fifth Annual Growth Conference
Sep 10, 07
06:00 ET	ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
Sep 04, 07
06:00 ET	ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
Aug 29, 07
06:00 ET	ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Aug 16, 07
06:00 ET	ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Aug 02, 07
16:01 ET	ADVENTRX Pharmaceuticals Reports Second Quarter 2007 Financial Results
Jul 31, 07
15:31 ET	ADVENTRX Reschedules Conference Call and Webcast Discussion of Second Quarter 2007 Results to August 2, 2007
Jul 26, 07
06:00 ET	ADVENTRX Pharmaceuticals to Host Conference Call and Webcast Discussion of Second Quarter 2007 Results on August 3, 2007
Jul 23, 07
06:00 ET	ANX-201 Combination Therapy Demonstrates Synergistic Inhibition of HIV-1 in Preclinical Tests
Jun 12, 07
06:00 ET	Jack Lief Named Chairman of ADVENTRX Pharmaceuticals
Jun 07, 07
06:00 ET	ADVENTRX Pharmaceuticals Receives Designation as a Small/Medium Enterprise by the European Medicines Agency
May 24, 07
09:30 ET	ADVENTRX Executes Agreement With United States Department of Veterans Affairs
May 14, 07
06:00 ET	ADVENTRX Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
May 09, 07
06:00 ET	ADVENTRX Pharmaceuticals to Present at Pharma Finance 2007 Conference
May 07, 07
16:01 ET	ADVENTRX Pharmaceuticals Reports First Quarter 2007 Financial Results
May 03, 07
03:00 ET	ANX-201 Drug Combination Demonstrates Synergistic Activity Against Human and Bird Flu Viruses
May 02, 07
06:00 ET	ADVENTRX Pharmaceuticals to Present at Biotechnology Industry Organization Annual Meeting
Apr 30, 07
06:00 ET	ADVENTRX Pharmaceuticals to Host Conference Call and Webcast Discussion of First Quarter 2007 Results on May 7, 2007
Apr 25, 07
06:00 ET	ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion)
Apr 23, 07
06:00 ET	ADVENTRX ANX-201 Abstract Accepted for Presentation at International AIDS Conference
Apr 18, 07
06:00 ET	ADVENTRX Announces Positive Data From Multidrug Therapy With CoFactor
Apr 11, 07
06:00 ET	ADVENTRX to Present at 7th Annual Fortis Biotech Conference
Apr 05, 07
06:00 ET	ADVENTRX Grants Manufacturing Contract for ANX-514 (Docetaxel Emulsion)
Apr 02, 07
06:00 ET	ADVENTRX to Present at CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference
Mar 29, 07
06:00 ET	ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual Meeting
Mar 26, 07
06:00 ET	ADVENTRX and TRx Pharma Announce Zanaflu(R) Registered as the Brand Name for ANX-211 (Chitosan Gel)
Mar 15, 07
16:00 ET	ADVENTRX Pharmaceuticals, Inc. Announces Fourth Quarter and Year 2006 Financial Results
Mar 13, 07
06:00 ET	ADVENTRX Appoints Vice President of Regulatory Affairs
Mar 07, 07
06:00 ET	ADVENTRX Pharmaceuticals to Report Fourth Quarter and Full Year 2006 Financial Results on March 15, 2007
Mar 06, 07
06:00 ET	ADVENTRX Announces M. Ross Johnson to Retire as Board Chairman
Feb 28, 07
05:00 ET	ADVENTRX to Present at BIO-Europe Spring Conference
Feb 12, 07
06:30 ET	ADVENTRX to Present Thiovir Preclinical Data at the 20th International Conference on Antiviral Research
Feb 05, 07
12:17 ET	ADVENTRX to Present at BIO CEO Conference
Jan 22, 07
06:00 ET	ADVENTRX to Present at the American Stock Exchange First Annual Healthcare Conference
Dec 27, 06
06:00 ET	ADVENTRX Initiates CoFactor Phase II Clinical Trial in Refractory Breast Cancer
Dec 26, 06
06:00 ET	ADVENTRX Cleared to Initiate Vinorelbine Emulsion Bioequivalence Study
Dec 20, 06
06:00 ET	ADVENTRX Announces Appointment of Veteran Finance and Biotech Industry Executive Gregory P. Hanson as Chief Financial Officer
Dec 07, 06
06:18 ET	ADVENTRX to Participate at the RBC Capital Markets Healthcare Conference
Nov 14, 06
06:00 ET	ADVENTRX to Present at BIOCOM San Diego Investor Conference
Nov 10, 06
06:00 ET	ADVENTRX Completes $40 Million Sale of Common Stock
Nov 09, 06
17:00 ET	ADVENTRX Announces 2006 Third Quarter Financial Results
Nov 03, 06
06:00 ET	ADVENTRX Announces $40 Million Common Stock Offering
Oct 31, 06
09:00 ET	ADVENTRX to Present at November Investor and Partnering Conferences
Oct 26, 06
13:43 ET	ADVENTRX Announces Board Change
Oct 23, 06
03:15 ET	ADVENTRX Licenses Proprietary Antiviral Product to Theragenex
Oct 12, 06
09:00 ET	ADVENTRX to Present at the BIO InvestorForum 2006
Sep 25, 06
04:00 ET	ADVENTRX Completes Enrollment in CoFactor Phase IIb Metastatic Colorectal Cancer Trial
Sep 22, 06
09:00 ET	ADVENTRX Appoints Jack Lief as Director
Sep 18, 06
04:00 ET	ADVENTRX Presents Positive Data Regarding CoFactor Combination in Colorectal Tumor Model
Sep 11, 06
04:00 ET	ADVENTRX to Present at UBS Global Life Sciences Conference
Sep 08, 06
18:20 ET	ADVENTRX Announces Senior Management Changes
Sep 05, 06
06:00 ET	ADVENTRX to Present at Think Equity Growth Conference
Aug 16, 06
06:00 ET	ADVENTRX Appoints Vice President of Medical Affairs
Aug 10, 06
06:00 ET	ADVENTRX Announces 2006 Second Quarter Financial Results
Aug 09, 06
07:30 ET	ADVENTRX Announces Appointment of General Counsel
Jul 24, 06
06:00 ET	ADVENTRX to Present CoFactor and UFT Preclinical Results
Jul 12, 06
06:00 ET	ADVENTRX Announces Redemption of Warrants
Jun 29, 06
06:00 ET	ADVENTRX Presents Encouraging New Supplemental Results for the CoFactor Phase II Metastatic Colorectal Cancer Trial
05:00 ET	ADVENTRX Presents CoFactor Pharmacokinetics Data
Jun 28, 06
13:57 ET	ADVENTRX Initiates CoFactor Phase III Clinical Trial
Jun 26, 06
08:00 ET	Data Safety Monitoring Board Recommends Continuation of ADVENTRX Phase IIb Clinical Trial for CoFactor
Jun 22, 06
05:00 ET	ADVENTRX Presents Broad Antiviral Activity for Thiovir
Jun 21, 06
09:30 ET	ADVENTRX Pharmaceuticals Set to Join Russell 3000 Index
Jun 20, 06
08:00 ET	ADVENTRX to Present Two CoFactor Clinical Abstracts at Gastrointestinal Cancer Conference
Jun 06, 06
04:00 ET	ADVENTRX to Present at the Pacific Growth Equities 2006 Life Sciences Growth Conference
Jun 05, 06
04:00 ET	ADVENTRX Announces Positive CoFactor Phase II Clinical Trial Results at ASCO Conference
May 30, 06
10:00 ET	ADVENTRX to Present CoFactor Phase II Results at ASCO Annual Conference
May 22, 06
09:21 ET	ADVENTRX Receives FDA Clearance Under a Special Protocol Assessment to Initiate CoFactor Phase III Clinical Trial
09:18 ET	ADVENTRX Announces Withdrawal of Public Stock Offering
May 16, 06
06:15 ET	ADVENTRX Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 10, 06
23:00 ET	ADVENTRX Announces 2006 First Quarter Financial Results
May 01, 06
21:51 ET	ADVENTRX Files Shelf Registration Statement
Apr 28, 06
04:00 ET	ADVENTRX Announces Closing of Merger With SD Pharmaceuticals
Apr 26, 06
04:00 ET	ADVENTRX to Present Positive Thiovir Antiviral Activity Results
Apr 13, 06
11:00 ET	ADVENTRX to Present at 6th Annual Fortis Bank Biotechnology Conference
Apr 10, 06
07:00 ET	ADVENTRX Signs Definitive Merger Agreement with SD Pharmaceuticals
Apr 06, 06
11:01 ET	ADVENTRX to Present at BIO 2006 Conference
Apr 05, 06
08:10 ET	ADVENTRX Presents Positive ANX-530 Preclinical Results
Apr 03, 06
04:00 ET	ADVENTRX Presents Positive Thiovir Preclinical Results
Mar 28, 06
04:30 ET	ADVENTRX Announces Upcoming Scientific Conference Presentations
Mar 23, 06
13:00 ET	ADVENTRX to Present at CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference
Mar 20, 06
14:26 ET	ADVENTRX Announces Thiovir Active Against H5N1 Avian Influenza Chimeric Virus Strains
14:21 ET	ADVENTRX to File Amended 2005 Third Quarter to Reflect Accounting for July 2005 Financing Under EITF 00-19
Mar 16, 06
21:27 ET	ADVENTRX Announces 2005 Fourth Quarter and Full Year Financial Results
Mar 09, 06
07:34 ET	ADVENTRX to Present at Bear Stearns Conference
Feb 14, 06
14:00 ET	ADVENTRX CoFactor Phase IIb Trial Surpasses 50% Enrollment Milestone
Feb 03, 06
14:00 ET	ADVENTRX to Present at BIO CEO on February 14
Jan 31, 06
11:30 ET	ADVENTRX Reports Thiovir Active Against Various Influenza A Viruses in Series of Independent Preclinical Tests
Jan 30, 06
06:01 ET	ADVENTRX Announces Positive Efficacy and Safety Results from CoFactor Phase II Clinical Trial
Jan 23, 06
10:00 ET	ADVENTRX Thiovir Preclinical Studies Slated for Presentation at HIV Pathogenesis Conference
Jan 19, 06
10:00 ET	Results From ADVENTRX Vinorelbine Preclinical Studies Accepted for Presentation at AACR Annual Meeting
Jan 17, 06
11:00 ET	ADVENTRX to Present CoFactor Phase II Data at ASCO Gastrointestinal Cancer Conference
Dec 07, 05
10:00 ET	ADVENTRX Announces Positive FDA Pre-IND Meeting Outcome
Dec 01, 05
08:30 ET	ADVENTRX to Present at Informed Investors Bay Area Biotechnology and Healthcare Forum
Nov 14, 05
18:18 ET	ADVENTRX Announces 2005 Third Quarter Financial Results
Nov 02, 05
08:06 ET	ADVENTRX to Present at November Conferences
Nov 15, 04
14:50 ET	ADVENTRX Pharmaceuticals Announces Third Quarter 2004 Results
Oct 22, 04
09:30 ET	ADVENTRX Pharmaceuticals to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference
Oct 14, 04
13:30 ET	CoFactor(TM) Granted Orphan Drug Status in the European Union for Pancreatic Cancer
Oct 11, 04
11:00 ET	ADVENTRX Pharmaceuticals to Present at the BIO Emerging Company Investor Forum
Oct 05, 04
10:00 ET	ADVENTRX Pharmaceuticals' Drug CoFactor(TM) Granted U.S. Orphan Drug Status by the FDA for Pancreatic Cancer